Experimental GLP-1 Pill Shows Promise for Weight Loss and Diabetes in Phase 2 Trials

Early Phase 2 clinical trial results indicate that elecoglipron, an experimental once-daily GLP-1 pill, helped participants control blood sugar and achieve significant weight loss. These findings, reported in The Lancet, suggest potential for a new treatment option. Developer AstraZeneca plans to advance elecoglipron to Phase 3 clinical trials.